( September 3, 2026, 10:46 AM EDT) -- NEW ORLEANS — The generic manufacturer of mifepristone, one of two drugs used to induce early termination of pregnancy, argues to the Fifth Circuit U.S. Court of Appeals that a case, which is scheduled for oral argument on Sept. 9, “is fundamentally flawed because Louisiana lacks standing” to bring the case asserting that the U.S. Food and Drug Administration’s 2023 decision that removed the in-person dispensing requirement for the drug was unconstitutional....